Asia-Pacific Tulathromycin Market Size, Share & Trends Analysis Report By Animal Type (Cattle, Swine) and By Country (China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2026-2034

Last Updated: September 18, 2026 | Author: Dhanashri Chandgude | Format:

Asia-Pacific Tulathromycin Market Size

The Asia-Pacific tulathromycin market size was valued at USD 419.25 million in 2025 and is projected to grow from USD 439.58 million in 2026 to reach USD 642.08 million by 2034, growing at a CAGR of 4.85% during the forecast period 2026–2034.

Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine.

Bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs are both treatable with tulathromycin, a macrolide antibiotic. Pfizer Inc. sells it under the brand name Draxxin. The 100-mg dose is contained in an injectable solution.

The Asia-Pacific tulathromycin market is driven by rising veterinary healthcare awareness. The entry of generic tulathromycin acts as a restraint on this market. On the other hand, the focus on animal welfare acts as an opportunity for the tulathromycin market.

Download a Free Sample To learn more about this report.

Animal Insights

Cattle dominated the market and is expected to register a CAGR of 8.9% over the forecast period. Tulathromycin treats and prevents bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cattle. Respiratory disease plays a significant role in weaned calf mortality, and bovine respiratory disease (BRD) morbidity affects survivability and reduces dairy performance later in life.

Asia-Pacific Tulathromycin Market Size By Segments

Request Customizationto receive a tailored report.

Asia-Pacific Tulathromycin Market Share By Segments

Speak to an Analystto discuss market opportunities.

Country Insights

The Asia-Pacific tulathromycin market is segmented based on the country: China, India, Japan, Southeast Asia, Korea, Australia, and the Rest of Asia-Pacific. China dominates the country's market and is expected to grow at a CAGR of 8.9% during the forecast period.

The second-largest market for tulathromycin is in Asia-Pacific. China and India currently hold the majority of the market. Cattle and swine have the highest population, which is primarily to blame.

For instance, China is home to more than 50% of the world's pigs. According to the most recent report from China's Ministry of Agriculture and Rural Affairs, domestic pigs will top 440 million by the end of 2021. In addition, the nation has a significant presence of cattle, totaling about 91.1 million.

India Tulathromycin Market Trends

India, on the other hand, is the largest nation with the highest population of cattle. Over 192 million people will live there by 2020, rising quickly. It has been noted that more farmers are diversifying their sources of income and turning to dairy farming as a secondary source of income in addition to traditional farming. As a result, tulathromycin demand is growing at a robust CAGR.

Most of the demand for tulathromycin is imported from China and India.

List of Key and Emerging Players in Asia-Pacific Tulathromycin Market

Zoetis

Zhejiang Genebest Pharmaceutical

Wisdom Pharmaceutical

Amicogen Biopharm

Hubei Honch Pharmaceutical

Livzon New North River Pharmaceutical

AVF Chemical Industrial

Jiangsu Lingyun Pharmaceutical

Key Industry Developments

May 2026

Zoetis expanded its livestock pharmaceutical portfolio across Asia-Pacific through strengthened commercialization and veterinary support programs for long-acting injectable antibiotics, including tulathromycin, for cattle and swine respiratory disease management.

April 2026

Ceva Santé Animale expanded its veterinary distribution network in Southeast Asia through new commercial partnerships supporting broader access to injectable antimicrobial products, including tulathromycin formulations.

February 2026

Virbac strengthened its livestock health business across Asia-Pacific by expanding technical training and veterinary education programs for respiratory disease treatment using long-acting injectable antibiotics.

October 2025

Huvepharma expanded regional distribution agreements for its veterinary injectable antimicrobial portfolio, improving the availability of tulathromycin-based products across selected Asia-Pacific markets.

Report Scope

Segmentation

By Animal Type 2

Cattle
Swine

Competitive Coverage Zoetis · Zhejiang Genebest Pharmaceutical · Wisdom Pharmaceutical · Amicogen Biopharm · Hubei Honch Pharmaceutical

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The market size is growing at a CAGR of 4.85% from 2026 to 2034.

rising veterinary healthcare awareness is the key driver for the growth of this market.

The key players in this market are The Zoetis,Zhejiang Genebest Pharmaceutical,Wisdom Pharmaceutical,Amicogen Biopharm,Hubei Honch Pharmaceutical Livzon New North River Pharmaceutical,AVF Chemical Industrial,Jiangsu Lingyun Pharmaceutical.

About the Author

Dhanashri Chandgude

Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.